Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine for Impulsivity in Bipolar Disorder
NCT05098353Unknown
- Sponsor
- Mental Health Research Center
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of quetiapine in bipolar disorder (BD), sponsored by Mental Health Research Center. Primary endpoints: Barratt Impulsiveness Scale at 6 weeks, Ballon Analog Risk Task at 6 weeks and 1 more. Status: unknown.
02
Drugs
quetiapine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT05098353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098353.